Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.

CD19 is a pan B-cell surface receptor expressed from pro-B-cell development until its down-regulation during terminal differentiation into plasma cells. CD19 represents an attractive immunotherapy target for cancers of lymphoid origin due to its high expression levels on the vast majority of non-Hodgkin's lymphomas and some leukemias. A humanized anti-CD19 antibody with an engineered Fc domain (XmAb5574) was generated to increase binding to Fcgamma receptors on immune cells and thus increase Fc-mediated effector functions. In vitro, XmAb5574 enhanced antibody-dependent cell-mediated cytotoxicity 100-fold to 1,000-fold relative to an anti-CD19 IgG1 analogue against a broad range of B-lymphoma and leukemia cell lines. Furthermore, XmAb5574 conferred antibody-dependent cell-mediated cytotoxicity against patient-derived acute lymphoblastic leukemia and mantle cell lymphoma cells, whereas the IgG1 analogue was inactive. XmAb5574 also increased antibody-dependent cellular phagocytosis and apoptosis. In vivo, XmAb5574 significantly inhibited lymphoma growth in prophylactic and established mouse xenograft models, and showed more potent antitumor activity than its IgG1 analogue. Comparisons with a variant incapable of Fcgamma receptor binding showed that engagement of these receptors is critical for optimal antitumor efficacy. These results suggest that XmAb5574 exhibits potent tumor cytotoxicity via direct and indirect effector functions and thus warrants clinical evaluation as an immunotherapeutic for CD19(+) hematologic malignancies.

[1]  H. Einsele,et al.  Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.

[2]  J. Desjarlais,et al.  Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells , 2008, Molecular Cancer Therapeutics.

[3]  A. Musolino,et al.  Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Parren,et al.  Tumor Cell Killing Mechanisms of Epidermal Growth Factor Receptor (EGFR) Antibodies Are Not Affected by Lung Cancer-Associated EGFR Kinase Mutations , 2008, The Journal of Immunology.

[5]  J. Falkenburg,et al.  Rituximab and Alemtuzumab in Combination, but Not Alone, Induce Complete Remissions in a Preclinical Animal Model of Primary Human ALL: Rationale for Combination Treatment. , 2007 .

[6]  H. Koeppen,et al.  High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate , 2007, British journal of haematology.

[7]  G. A. Lazar,et al.  Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. , 2007, Drug discovery today.

[8]  J. Stavenhagen,et al.  Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. , 2007, Cancer research.

[9]  B. Bonavida,et al.  ‘Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions’ , 2007, Oncogene.

[10]  Herren Wu,et al.  Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. , 2007, Journal of molecular biology.

[11]  P. Hoffmann,et al.  CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. , 2007, Molecular immunology.

[12]  G. A. Lazar,et al.  A molecular immunology approach to antibody humanization and functional optimization. , 2007, Molecular immunology.

[13]  P. Carter,et al.  Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. , 2007, Blood.

[14]  A. Baras,et al.  Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity , 2006, Springer Seminars in Immunopathology.

[15]  B. Cheson.  Monoclonal antibody therapy for B-cell malignancies. , 2006, Seminars in oncology.

[16]  G. A. Lazar,et al.  Engineered antibody Fc variants with enhanced effector function. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[17]  T. Tedder,et al.  Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy , 2006, The Journal of experimental medicine.

[18]  D. Saul,et al.  Influence of Variable N-Glycosylation on the Cytolytic Potential of Chimeric CD19 Antibodies , 2006, Journal of immunotherapy.

[19]  J. Ravetch,et al.  Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding , 2005, Science.

[20]  Brian J. Smith,et al.  Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. , 2005, Blood.

[21]  T. Tedder,et al.  Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Lang,et al.  Effective lysis of lymphoma cells with a stabilised bispecific single‐chain Fv antibody against CD19 and FcγRIII (CD16) , 2005, British journal of haematology.

[23]  E. Kimby,et al.  Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  K. Haas,et al.  The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy , 2004, The Journal of experimental medicine.

[25]  W. Weng,et al.  Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Kimberly,et al.  FcγRs Modulate Cytotoxicity of Anti-Fas Antibodies: Implications for Agonistic Antibody-Based Therapeutics1 , 2003, The Journal of Immunology.

[27]  T. Sieber,et al.  Selective internalization of monoclonal antibodies by B‐cell chronic lymphocytic leukaemia cells , 2003, British journal of haematology.

[28]  H. Kantarjian,et al.  Anti-B4 Blocked Ricin Post Chemotherapy in Patients with Chronic Lymphocytic Leukemia--Long-term Follow-up of a Monoclonal Antibody-based Approach to Residual Disease , 2003, Leukemia & lymphoma.

[29]  Theresa M Allen,et al.  Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. , 2002, Cancer research.

[30]  P. Marlton,et al.  Incidence and nature of CD20‐negative relapses following rituximab therapy in aggressive B‐cell non‐Hodgkin's lymphoma: a retrospective review , 2002, British journal of haematology.

[31]  G. Salles,et al.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.

[32]  S. Pierce,et al.  The Role of the CD19/CD21 Complex in B Cell Processing and Presentation of Complement-Tagged Antigens , 2001, The Journal of Immunology.

[33]  Leonard G. Presta,et al.  High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR* , 2001, The Journal of Biological Chemistry.

[34]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[35]  D. Czerwinski,et al.  Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  L. Ginaldi,et al.  Levels of expression of CD19 and CD20 in chronic B cell leukaemias. , 1998, Journal of clinical pathology.

[37]  M. Inaoki,et al.  The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. , 1997, Immunity.

[38]  W. Wade,et al.  Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and either CD19, CD20, CD95 or surface immunoglobulin. , 1996, Immunopharmacology.

[39]  C. Schoot,et al.  Fc gamma receptor II (CD32) on malignant B cells influences modulation induced by anti-CD19 monoclonal antibody , 1994 .

[40]  G. Pietersz,et al.  Preclinical investigation of the antitumour effects of anti-CD19-idarubicin immunoconjugates , 1993, Cancer Immunology, Immunotherapy.

[41]  J. Taylor,et al.  Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  S. Levy,et al.  The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. , 1992, Journal of immunology.

[43]  A. Farr,et al.  Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. , 1989, Cancer research.

[44]  G. Pinkus,et al.  Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. , 1984, Blood.

[45]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[46]  E. Sotomayor,et al.  Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. , 2007, Hematology. American Society of Hematology. Education Program.

[47]  J. Sein,et al.  Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19 , 2005, Cancer Immunology, Immunotherapy.

[48]  S. Rodenhuis,et al.  Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody , 2005, Cancer Immunology, Immunotherapy.

[49]  W. Chan,et al.  New approaches to lymphoma diagnosis. , 2001, Hematology. American Society of Hematology. Education Program.

[50]  C. E. van der Schoot,et al.  Fc gamma receptor II (CD32) on malignant B cells influences modulation induced by anti-CD19 monoclonal antibody. , 1994, Blood.

[51]  L. Chatenoud,et al.  Antigenic modulation - a major mechanism of antibody action. , 1984, Immunology today.

[52]  R. Warnke,et al.  A unique human B lymphocyte antigen defined by a monoclonal antibody. , 1984, Hybridoma.